Marqibo for the Treatment of Older Patients With ALL

March 31, 2014
Eunice Wang, MD

Eunice Wang, MD, discusses an ongoing phase III trial looking at vincristine sulfate liposomes injection (Marqibo) for the treatment of patients ≥ 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).

Clinical Pearls

Eunice Wang, MD, associate professor, Department of Medicine, Roswell Park Cancer Institute, discusses an ongoing phase III trial looking at vincristine sulfate liposomes injection (Marqibo) for the treatment of patients ≥ 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).

  • ALL is highly curable in pediatric patients, though the cure rate in adults is only 40-50%
  • Patients in this trial are randomized to receive either standard chemotherapy or standard chemotherapy in addition to Marqibo
  • Marqibo is currently approved in the relapsed/refractory setting but has not been tested in older adults